# Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer

> **NCT02288936** · PHASE2 · COMPLETED · sponsor: **Spanish Oncology Genito-Urinary Group** · enrollment: 98 (actual)

## Conditions studied

- Hormone-refractory Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT02288936
- **Lead sponsor:** Spanish Oncology Genito-Urinary Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-05
- **Primary completion:** 2019-07-22
- **Final completion:** 2019-07-22
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2019-09-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02288936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02288936, "Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02288936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*